A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck.

Trial Profile

A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jan 2013 Planned end date changed from 1 May 2011 to 1 Jun 2020 as reported by ClinicalTrials.gov
    • 08 Apr 2009 Additional lead trial centre University of Maryland and Baltimore Veterans Affairs Medical Centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top